A clinical case of using ribociclib with an aromatase inhibitor in metastatic hormone-receptor-positive HER2-negative breast cancer with a rare location of metastasis


DOI: https://dx.doi.org/10.18565/pharmateca.2019.12.121-125

A.V. Fateeva (1), A.V.Zyuzyukina (2), R.A. Zukov (2)

1) Primorsky Regional Oncology Center, Vladivostok, Russia; 2) Voino-Yasenetsky Krasnoyarsk State Medical University, Krasnoyarsk, Russia
Background. Domestic literature is lacking descriptions of rare locations of breast cancer metastases and their management using CDK 4/6 inhibitors.
Description of the clinical case. In 2009, the patient underwent combination therapy for T2N2M0 breast cancer. In 2015, the disease recurred in the area of the postoperative scar and was managed with surgical excision followed by tamoxifen therapy. In 2018, she was found to have multiple liver metastases and a rare cervical metastasis. Chemotherapy with cisplatin + gemcitabine was initiated. After the second course of chemotherapy, the patient developed multiple skeletal bone metastases. She was administered combination therapy with aromatase inhibitors and CDK 4/6. A good clinical response was observed with minor toxicity.
Conclusion. In the presented clinical case, CDK4/6 endocrine therapy of metastatic breast cancer potentiated by inhibitors was highly effective (a 26% reduction of liver lesions, complete response of the cervical tumor, and resolution of bone pain) and had an acceptable toxicity profile.

About the Autors


Corresponding author: Ruslan A. Zukov, MD, Professor, Head of the Department of Oncology and Radiation Therapy with a Course of Postgraduate Education, Voino-Yasenetsky Krasnoyarsk State Medical University, Krasnoyarsk, Russia; e-mail: zukov_rus@mail.ru; ORCID: https://orcid.org/0000-0002-7210-3020, Scopus Author ID: https://www.scopus.com/authid/detail.uri?authorId=6508181003 
Address: 1, Partizan Zheleznyak Street, Krasnoyarsk 660022, Russian Federation


Similar Articles


Бионика Медиа